Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
Overview | Financials
Company Name | Crinetics Pharmaceuticals, Inc. |
Symbol | CRNX |
Currency | USD |
Price | 56.82 |
Market Cap | 5,115,822,792 |
Dividend Yield | 0% |
52-week-range | 25.75 - 60.04 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. R. Scott Struthers Ph.D. |
Website | https://www.crinetics.com |
An error occurred while fetching data.
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD